Cidara Therapeutics Inc CDTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CDTX is a good fit for your portfolio.
News
-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
-
Cidara Therapeutics Announces Receipt of Nasdaq Delinquency Notice
-
Cidara Therapeutics Announces Reverse Stock Split
-
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024
-
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
-
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
-
Cidara Shares Rally Premarket as J&J Moves Forward on Influenza Pact
Trading Information
- Previous Close Price
- $0.51
- Day Range
- $0.50–0.58
- 52-Week Range
- $0.50–1.48
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $46.44 Mil
- Volume/Avg
- 1.9 Mil / 768,617
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.70
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's REZZAYO® (rezafungin for injection) is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 73
- Website
- https://www.cidara.com
Comparables
Valuation
|
Metric
|
CDTX
|
AVIR
|
AMLX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 1.68 |
Price/Book Value | — | 0.56 | 0.31 |
Price/Sales | 0.70 | — | 0.36 |
Price/Cash Flow | — | — | 1.79 |
Price/Earnings
CDTX
AVIR
AMLX
Financial Strength
|
Metric
|
CDTX
|
AVIR
|
AMLX
|
|---|---|---|---|
Quick Ratio | 0.77 | 17.86 | 5.01 |
Current Ratio | 0.90 | 18.24 | 5.66 |
Interest Coverage | — | — | — |
Quick Ratio
CDTX
AVIR
AMLX
Profitability
|
Metric
|
CDTX
|
AVIR
|
AMLX
|
|---|---|---|---|
Return on Assets (Normalized) | −31.30% | −15.46% | 18.55% |
Return on Equity (Normalized) | −371.06% | −16.16% | 21.48% |
Return on Invested Capital (Normalized) | −253.14% | −19.92% | 17.45% |
Return on Assets
CDTX
AVIR
AMLX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Wprhphhfvb | Rtlxc | $557.8 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Lgfgmrls | Mvwtht | $104.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Lbjjlzkwg | Mlbvrpy | $98.8 Bil | |
MRNA
| Moderna Inc | Qzkywwjzk | Bhf | $38.8 Bil | |
ARGX
| argenx SE ADR | Wcrlvhlcc | Tsbwy | $21.4 Bil | |
BNTX
| BioNTech SE ADR | Gtnmlmpkh | Ccjgn | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mfvwqtl | Zsktsc | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jnmpmtffh | Tlqyts | $17.5 Bil | |
RPRX
| Royalty Pharma PLC Class A | Lxpqhwrsl | Gcqsq | $12.4 Bil | |
INCY
| Incyte Corp | Hjzcwzjzk | Yyjjjd | $11.9 Bil |